Physician profile
Mark Joseph
NPI 1740242320
$144,187.28
in general payments reported to CMS, 2019-2025
12 companies · $9,500 in 2025
The $9,500 reported for 2025 was more than what 92% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $13K · 2021: $9,639 · 2022: $26K · 2023: $25K · 2024: $27K · 2025: $9,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Honoraria: $21K · Travel and Lodging: $4,870 · Consulting Fee: $4,038 · Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,112.50 |
| Honoraria | $20,862.00 |
| Travel and Lodging | $4,869.64 |
| Consulting Fee | $4,037.50 |
| Food and Beverage | $660.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $107,101.06 | 2019-2023 | Procysbi |
| Amgen INC. | $36,386.27 | 2024-2025 | Procysbi |
| Aurinia Pharma U.S., INC. | $232.54 | 2021 | |
| Mallinckrodt Enterprises LLC | $156.24 | 2019 | |
| Alexion Pharmaceuticals, INC. | $63.52 | 2019-2022 | |
| Vifor Pharma, INC. | $59.78 | 2019 | |
| Genzyme Corporation | $51.30 | 2019 | |
| Mallinckrodt Hospital Products INC. | $48.36 | 2020 | |
| Leadiant Biosciences, INC. | $33.62 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $20.44 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.